JD.Com Inc vs Zoetis Inc — how do they compare? JD.Com Inc trades at $31.15 (market cap $44.04B), while Zoetis Inc trades at $72.25 (market cap $31.14B). The key difference: JD.Com Inc is the larger of the two by market cap, and JD.Com Inc pays the higher dividend (3.13%). Which is the better fit depends on your goals.
| JD | ZTS | |
|---|---|---|
Market Cap | $44.04B | $31.14B |
Sector | Consumer Cyclical | Health |
52-Week High | $36.17 | $156.76 |
52-Week Low | $25.19 | $71.91 |
Enterprise Value | $30.10B | $38.70B |
Dividend Yield | 3.13% | 2.81% |
Signals from Pluang's Aura AI — not financial advice
JD.com trades at $33.47, up 1.52% today, with a bullish technical setup as price consolidates near recent highs. The company reported strong Q1 2026 earnings, beating estimates with EPS of $0.74 versus $0.57 expected, while revenue reached $1.31 trillion in 2025. Analyst consensus remains strongly positive with a $38.00 price target, though regulatory scrutiny from EU authorities over the Ceconomy acquisition presents a near-term headwind.
JD offers attractive valuation with a P/S of 0.24 and consistent earnings beats, but faces margin pressure and regulatory risks. Upside potential exists if Q2 2026 results meet high expectations, but investors must weigh competitive pressures in e-commerce and macroeconomic challenges affecting Chinese equities.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Trailing returns across standard periods
Latest headlines on both assets
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →